Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies.

Seyed Jafari, S Morteza; Heidemeyer, Kristine; Hunger, Robert E; de Viragh, Pierre A. (2024). Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies. Journal of clinical medicine, 13(11) MDPI 10.3390/jcm13113052

[img]
Preview
Text
jcm-13-03052.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (262kB) | Preview

The most common type of alopecia in women is female androgenetic alopecia (FAGA), characterized by progressive hair loss in a patterned distribution. Many oral therapies, including spironolactone (an aldosterone antagonist), androgen receptor blockers (e.g., flutamide/bicalutamide), 5-alpha-reductase inhibitors (e.g., finasteride/dutasteride), and oral contraceptives, target the mechanism of androgen conversion and binding to its respective receptor and therefore could be administered for the treatment of FAGA. Despite significant advances in the oral treatment of FAGA, its management in patients with a history of gynecological malignancies, the most common cancers in women worldwide, may still be a concern. In this review, we focus on the safety of antiandrogens for the treatment of FAGA patients. For this purpose, a targeted literature review was conducted on PubMed, utilizing the relevant search terms. To sum up, spironolactone seems to be safe for the systemic treatment of FAGA, even in high-risk populations. However, a general uncertainty remains regarding the safety of other medications in patients with a history of gynecologic malignancies, and further studies are needed to evaluate their long-term safety in patients with FAGA and risk factors to establish an optimal risk assessment and treatment selection protocol.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Jafari, Morteza, Heidemeyer, Kristine, Hunger, Robert, de Viragh, Pierre A.

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2077-0383

Publisher:

MDPI

Language:

English

Submitter:

Pubmed Import

Date Deposited:

20 Jun 2024 14:11

Last Modified:

20 Jun 2024 14:21

Publisher DOI:

10.3390/jcm13113052

PubMed ID:

38892763

Uncontrolled Keywords:

5α-reductase inhibitors androgenetic alopecia cyproterone acetate dutasteride finasteride gynecologic malignancies safety spironolactone

BORIS DOI:

10.48350/197952

URI:

https://boris.unibe.ch/id/eprint/197952

Actions (login required)

Edit item Edit item
Provide Feedback